Versartis to Present at Cowen & Co. Annual Healthcare Conference and Barclays Global Healthcare Conference

MENLO PARK, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. VSAR, an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that the Company is scheduled to present at two upcoming investor conferences. Details are as follows:

Audio webcasts of the Company's presentations will be available on the investor relations section of the Versartis' website at www.versartis.com.  A replay of the presentation will be available for 90 days.

About Versartis, Inc.
Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing somavaratan, a novel, long-acting form of recombinant human growth hormone in late-stage clinical trials for the treatment of GHD in children and adults.  Somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving adherence and, therefore, treatment outcomes.  For more information on Versartis, visit www.versartis.com.

Contacts:

Corporate Communications: 
Christine Labaree
Corporate Affairs
(650) 600-1697
clabaree@versartis.com

Investors:
David Burke
Director, Investor Relations
(650) 516-2703 
dburke@versartis.com